Remogliflozin  (Synonyms: Remogliflozin A)

Remogliflozin (Remogliflozin A) is an orally active, highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, with a K_i of 12.4 nM for human SGLT2 and 26.0 nM for rat SGLT2. Remogliflozin increases urinary glucose excretion by inhibiting renal glucose reabsorption. Without insulin stimulation, remogliflozin suppresses the elevation of plasma glucose, reduces fasting blood glucose and glycated hemoglobin, and improves glycosuria, hyperglycemia, hyperinsulinemia, hypertriglyceridemia and insulin resistance in diabetic rodents. Remogliflozin can be used in research related to type 2 diabetes^[1][2].

Remogliflozin (4h cell seeding culture; 2 days post-transfection assay) is a potent and highly selective SGLT2 inhibitor, with a K_i of 12.4 nM for human SGLT2 and a 365-fold selectivity for human SGLT2 over human SGLT1, and a K_i of 26.0 nM for rat SGLT2 with a 38-fold selectivity for rat SGLT2 over rat SGLT1, in transiently transfected COS-7 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

450.53

C₂₃H₃₄N₂O₇

329045-45-6

Solid

Light yellow to yellow

O[C@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)[C@@H]1OC2=NN(C(C)C)C(C)=C2CC3=CC=C(OC(C)C)C=C3

Room temperature in continental US; may vary elsewhere.

• [1]. Fujimori Y, et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther. 2008;327(1):268-276.  [Content Brief]

  [2]. Atal S, et al. Remogliflozin: the new low cost SGLT-2 inhibitor for type 2 diabetes mellitus. Diabetol Int. 2020;12(3):247-253. Published 2020 Oct 29.